EisaiEisai Glossary Eisai Glossary

 Eisai product names 
Generic name: adalimumab. Rheumatoid arthritis treatment first launched in June 2008. World's first fully human anti-TNF-α monoclonal antibody. Exerts effects by neutralizing TNF-α (tumor neurosis factor-α), a protein that plays a central role in inflammatory responses in rheumatoid arthritis and other immune-mediated inflammatory diseases. Jointly developed and co-promoted in Japan by Eisai and AbbVie GK. In addition to rheumatoid arthritis (including inhibition of structural damage), currently approved indications for this drug include psoriasis, Crohn's disease, ankylosing spondylitis, juvenile idiopathic arthritis, intestinal Behçet's disease, and ulcerative colitis.


Copyright (C) Eisai Co., Ltd. All Rights Reserved.